Summit Therapeutics (SMMT) Reports Positive Results from the Phase III HARMONi Trial

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 15 stocks set to explode in 2026.

On November 7, 2025, Summit Therapeutics Inc. (NASDAQ:SMMT) announced results from the Phase III HARMONi trial conducted in China. The results were published by its partner Akeso, Inc.

The study tested ivonescimab, an innovative bispecific antibody, combining it with platinum-doublet chemotherapy in patients whose lung cancer had a specific genetic mutation (EGFR) and whose cancer was advanced or had spread. Furthermore, these patients were those who had already been treated with EGFR-TKI therapy.

A statistically significant improvement in overall survival was noted by the trial, marked by a median OS of 16.8 months for ivonescimab plus chemotherapy versus 14.1 months for chemotherapy alone. Ivonescimab demonstrated a manageable safety profile, in line with previous Phase III studies.

With these results, Summit Therapeutics Inc. (NASDAQ:SMMT) highlighted ivonescimab’s potential to cater to high unmet medical needs in NSCLC. The antibody promises to offer efficacy where PD-1 therapies had previously failed. Thus, the therapy’s momentum solidifies further as over 40,000 patients in China have already been treated with ivonescimab across clinical and commercial settings.

Previously, on November 3, 2025, Truist Financial analyst Asthika Goonewardene maintained a “Buy” rating on Summit Therapeutics Inc. (NASDAQ: SMMT).

Summit Therapeutics Inc. (NASDAQ:SMMT), a biopharmaceutical company specializing in oncology, develops innovative therapies, with ivonescimab being its lead development candidate.

While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Fortune 500 Stocks to Invest in Now and 13 Best Fortune 500 Stocks to Invest in Now.

Disclosure: None.